EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

Adrián Segura-Díaz, Ruth Stuckey, Yanira Florido, Marta Sobas, Alberto Álvarez-Larrán, Francisca Ferrer-Marín, Manuel Pérez-Encinas, Gonzalo Carreño-Tarragona, María L Fox, Barbara Tazón Vega, Beatriz Cuevas, Juan F López Rodríguez und 5 weitere

Thrombosis and Haemostasis · 01.07.2024 · 124 (07) · 669-675

DOI: 10.1055/a-2239-9265 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.07.2024. Verfasst von Adrián Segura-Díaz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. Hauptthemen laut MEDLINE: Dioxygenases, Thrombosis, Mutation, DNA Methyltransferase 3A. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundación DISA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment recommendations, vascular events remain frequent, leading us to question whether thrombotic risk stratification could be improved. We previously reported an association between thrombotic events and mutations in DTA genes (DNMT3A, TET2, and ASXL1). The objective of this study was to confirm this observation in a larger series of PV patients.

Methods

PV patients with a minimum follow-up of 3 years were recruited from 8 European centers. Medical history was searched for thrombotic event recorded at any time and next-generation sequencing carried out with a myeloid panel. Multivariable logistic regression evaluated the impact of variables on thrombotic risk. Kaplan–Meier thrombosis-free survival curves were compared by the log rank test. Associations in the total cohort were confirmed in a case–control study to exclude selection bias.

Results

Of the 136 patients recruited, 74 (56.1%) had a thrombotic event, with an incidence density of 2.83/100 person-years. In multivariable analysis, DTA mutation was a risk factor for thrombotic event, being predictive for shorter thrombosis-free survival in the whole cohort (p = 0.007), as well as in low-risk patients (p = 0.039) and older patients (p = 0.009), but not for patients with a prediagnostic event. A gender- and age-matched case–control study confirmed the increased risk of thrombotic event for PV patients with a DTA mutation.

Conclusion

Our results support the use of molecular testing at diagnosis to help predict which PV patients are at higher risk of developing thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DioxygenasesThrombosisMutationDNA Methyltransferase 3APolycythemia VeraRepressor ProteinsProto-Oncogene ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA-Binding ProteinsHumansMaleFemaleMiddle AgedRisk FactorsAgedAge FactorsCase-Control StudiesAdultEuropeIncidenceGenetic Predisposition to DiseaseRisk AssessmentKaplan-Meier EstimateAged, 80 and over

Substanzen

DioxygenasesDNA Methyltransferase 3ATET2 protein, humanDNMT3A protein, humanRepressor ProteinsASXL1 protein, humanProto-Oncogene ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA-Binding Proteins

Autor:innen und Institutionen

  • Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
  • Department of Hematology and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland.
  • Hematology Department, Hospital Clínic, Barcelona, Spain.
  • Hematology Department, Hospital Morales Messeguer, Instituto Murciano de Investigación Biosanitaria, Centro de Investigación Biomédica en Red de Enfermedades Raras, Universidad Católica San Antonio de Murcia, Murcia, Sp…
  • Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Förderung

  • Fundación DISA

Zitieren

APA

Segura-Díaz, A., Stuckey, R., Florido, Y., Sobas, M., Álvarez-Larrán, A., Ferrer-Marín, F., Pérez-Encinas, M., Carreño-Tarragona, G., Fox, M. L., Tazón Vega, B., Cuevas, B., López Rodríguez, J. F., Sánchez-Farías, N., González-Martín, J. M., Gómez-Casares, M. T., Bilbao-Sieyro, C., & Spanish MPN Group (GEMFIN) (2024). DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study. Thrombosis and Haemostasis, 124(07), 669-675. https://doi.org/10.1055/a-2239-9265

Vancouver

Segura-Díaz A, Stuckey R, Florido Y, Sobas M, Álvarez-Larrán A, Ferrer-Marín F, et al. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study. Thrombosis and Haemostasis. 2024;124(07):669-675. doi:10.1055/a-2239-9265

BibTeX
@article{SeguraDaz2024,
  author = {Segura-Díaz, Adrián and Stuckey, Ruth and Florido, Yanira and Sobas, Marta and Álvarez-Larrán, Alberto and Ferrer-Marín, Francisca and Pérez-Encinas, Manuel and Carreño-Tarragona, Gonzalo and Fox, María L and Tazón Vega, Barbara and Cuevas, Beatriz and López Rodríguez, Juan F and Sánchez-Farías, Nuria and González-Martín, Jesús M and Gómez-Casares, María T and Bilbao-Sieyro, Cristina and Spanish MPN Group (GEMFIN), Spanish MPN Group (GEMFIN)},
  title = {DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {07},
  pages = {669--675},
  doi = {10.1055/a-2239-9265}
}
Kostenlos starten →